TeamDrive
RUS

Russia approves the plan for Development of Biotechnology and Genetic Engineering

13 March 2018

GMP News

The Russian government adopted the action plan (roadmap) for the Development of Biotechnology and Genetic Engineering in 2018 – 2020.

The plan aims at developing domestic demand, manufacturing and exports of biotech products, and building institutional environment in order to modernize the technology base of the industry through mass introduction of biotech methods and products.

It provides for further expansion of production potential and cooperation in the area of biomedicine and biopharmaceuticals, agricultural and industrial biotechnology, bioenergetics, forest and environmental biotechnology, and genetic engineering.

By 2020, 2 common use production centers licensed for manufacturing biomedical cell products will be established to conduct R&D and pre-clinical studies of biomedical cell products.

The number of medical institutions accredited for clinical trials of biomedical cell products will be increased from 5 to 50.


Previous publication Next publication

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more